Orchid Chemicals & Pharmaceuticals Ltd : Orchid Pharma registers 6% growth in FY12. Long-term supply contracts continue to add value to earnings. – 4-traders (press release)

Of these 28 DMFs pertain to the Cephalosporin category, 47 to NPNCs, 2 to the Betalactam segment and 12 to the Carbapenems segment. Similarly, the filings of COS (Certificate of Suitability) for the European market stood at 21 which includes 14 in …

Leave a Reply

Your email address will not be published.